These trials collectively demonstrate that CTLA-4 inhibition, particularly in combination with PD-1/PD-L1 blockade, represents a meaningful therapeutic advance for HCC patients, with the STRIDE regimen now establishing a new standard of care for first-line treatment of unresectable disease. Here, CTLA4 is linked to hepatocellular carcinoma.